Celcuity Submits SNDA To FDA For REVTORPYK In Advanced Breast Cancer
Celcuity Inc. (CELC) submitted a supplemental New Drug Application to the FDA for REVTORPYK, an investigational therapy for advanced breast cancer with a PIK3CA mutation. The application is supported by Phase 3 trial data showing significant improvements in progression-free survival and response rates. If approved, REVTORPYK would be the first therapy of its kind for this patient population. CELC stock closed at $92.27, up 1.63%.
How this was made
The 30-second read
Why it matters
The FDA submission introduces a new therapeutic option for HR+/HER2‑ advanced breast cancer, potentially expanding market share.
Market read
Regulatory filing is a catalyst for biotech equities; investors will watch the FDA decision closely.
What to watch
Competition from existing PI3K inhibitors and reimbursement uncertainties.
Background
Celcuity is a clinical‑stage biotech focused on PI3K/mTOR pathway inhibitors.
Ticker impact
Celcuity submitted an FDA supplemental NDA for REVTORPYK, a new PI3K/mTOR inhibitor for advanced breast cancer.
Upward pressure if FDA grants approval; downside risk if denied.
Regulatory filing is a primary, material event for a biotech with a large unmet market.
Market effects
May spur interest in other PI3K/mTOR targeted therapies and boost sector sentiment.
Limited to US biotech market; no broader regional effect.
Potentially relevant to global oncology drug pipeline investors.
Counterpoint
Regulatory risk remains high; FDA may request additional data, delaying launch.
Key entities
- CompanyCelcuity Inc.
Biotech developer of REVTORPYK.
- RegulatorFDA
U.S. agency reviewing the supplemental NDA.
